Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Detailed description
The study will consist of two parts. Part A is a parallel group, placebo-controlled single dose study to ascertain the Pharmacokinetics (PK) profile, safety and bronchodilator effect of RPL554 administered via dry powder inhaler (DPI). Five of the 6 treatment arms will be double-blind and one will be single-blind (due to the different number of capsules administered). Part B is a placebo-controlled, complete block cross-over, repeat dose study to assess the bronchodilator effect of repeat doses of RPL554 delivered via a DPI.
Interventions
DRUGPart A: RPL554
1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
DRUGPart B: RPL554
Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
DRUGPlacebos
Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler. Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Sponsors
Iqvia Pty Ltd
Verona Pharma plc
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study. 2. For males, not to donate sperm and either be sexually abstinent or use contraception as specified by the protocol. For females, be of non-childbearing potential or use a highly effective form of contraception 3. 12-lead ECG with heart rate between 45 and 90 beats per minute, QTcF ≤450 msec for males, and ≤ 470 msec for females, QRS interval ≤120 msec and no clinically significant abnormality including morphology 4. Capable of complying with all study restrictions and procedures including ability to use the DPI correctly. 5. Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) with a minimum weight of 45 kg. 6. COPD diagnosis for 1 year \[prior to screening 7. Ability to perform acceptable and reproducible spirometry. 8. Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating the following: * FEV1/Forced Vital Capacity (FVC) ratio of ≤0.70 * FEV1 ≥40 % and ≤80% of predicted normal * ≥150 mL increase from pre-bronchodilator FEV1 9. Clinically stable COPD in the 4 weeks prior to Screening and during the period between Screening and Part A. 10. A chest X-ray showing no abnormalities, which are both clinically significant and unrelated to COPD. 11. Meet the concomitant medication restrictions and be expected to do so for the rest of the study. 12. Current and former smokers with smoking history of ≥10 pack years. 14. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to dosing.
Exclusion criteria
1. A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation. 2. COPD exacerbation requiring oral or parenteral steroids, or lower respiratory tract infection requiring antibiotics, within 3 months of Screening or prior to Part A. 3. A history of one or more hospitalizations for COPD or pneumonia within 6 months of Screening or prior to Part A. 4. Intolerance or hypersensitivity to tiotropium, olodaterol, atropine, ipratropium, or RPL554. 5. Evidence of cor pulmonale or clinically significant pulmonary hypertension. 6. Other respiratory disorders 7. Previous lung resection or lung reduction surgery. 8. Use of immunosuppressive therapy, including oral corticosteroids 9. Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study. 10. History of, or reason to believe a patient has, drug or alcohol abuse within the past 5 years. 11. Received an experimental drug within 30 days or five half lives, whichever is longer. 12. Patients with uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant. 13. Documented cardiovascular disease, including any history of arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension within 3 months prior to Screening 14. Use of non-selective oral β-blockers. 15. Major surgery (requiring general anesthesia) within 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study. 16. A disclosed history or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications. 17. Required use of oxygen therapy, even on an occasional basis. 18. History of malignancy of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell). 19. Clinically significant abnormal values for safety laboratory tests (hematology, biochemistry, viral serology or urinalysis) at Screening, as determined by the Investigator. In particular, alanine aminotransferase or aspartate aminotransferase cannot be more than twice the upper limit of normal. 20. Any other reason that the Investigator considers makes the patient unsuitable to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | Day 1 | RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose |
| Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | Day 1 | RPL554 Area under the curve at maximum concentration after a single dose |
| Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | Day 1 | RPL554 Plasma pharmacokinetics Half-life concentration after a single dose |
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | Day 7 | Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | Day 1 | Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose |
| Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | Day 1 | Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose |
| Part A: Safety and Tolerability / Hematology Safety Assessments | Day 1 | number of patients with treatment-emergent hematology abnormal laboratory assessments |
| Part A: Safety and Tolerability / Blood Chemistry Safety Assessments | Day 1 | number of patients with treatment-emergent blood chemistry abnormal laboratory assessments |
| Part A: Safety and Tolerability / Urinalysis Safety Assessments | Day 1 | number of patients with treatment-emergent urinalysis abnormal laboratory assessments |
| Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate | Day 1 | Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose |
| Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure | Day 1 | number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp) |
| Part A: Safety and Tolerability / ECG - QTcF | Day 1 | number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec |
| Part A: Safety and Tolerability / ECG - Heart Rate | Day 1 | number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm |
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | Day 1 | Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose |
| Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | Day 1 | Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1 |
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | Day 1 | Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1 |
| Part B: Change From Baseline in Trough FEV1 | Day 7 | Change from Baseline FEV1 to Morning Trough FEV1 on Day 7 |
| Part B: Safety and Tolerability / Blood Chemistry Safety Assessments | Day 7 | number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group). |
| Part B: Safety and Tolerability / Urinalysis Safety Assessments | Day 7 | number of patients with treatment-emergent urinalysis abnormal laboratory assessments |
| Part B: Safety and Tolerability / ECG - QTcF | Day 7 | number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec |
| Part B: Safety and Tolerability / ECG - Heart Rate | Day 7 | number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm |
| Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate | Day 7 | number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20 |
| Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure | Day 7 | number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20) |
| Part B: Change From Baseline in Peak Pulse Rate (Day 1) | Day 1 | Change from baseline in peak pulse after first dose on Day 1 |
| Part B: Change From Baseline in Peak Pulse Rate (Day 7) | Day 7 | Change from baseline in peak pulse after morning dosing on Day 7 |
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | Day 7 | RPL554 steady-state PK (tmax) after morning dose on Day 7 |
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | Day 7 | RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7 |
| Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | Day 7 | RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7 |
| Part B: Safety and Tolerability / Hematology Safety Assessments | Day 7 | number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group). |
| Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | Day 7 | Change from baseline in average FEV1 (over 4 hours) on Day 7 |
| Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | Day 7 | Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7 |
| Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | Day 1 | Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose |
Countries
United States
Participant flow
Recruitment details
37 subjects enrolled for Part A and anticipated to continue into Part B.
Pre-assignment details
Part A: 37 Patients randomized equally to receive a single dose of RPL554 (0.15, 0.5, 1.5, 3, or 6 mg) or matching placebo via dry powder inhaler (DPI). Patients were to continue to Part B after Part A is complete. Part B: 35 Patients continued from Part A and randomly assigned to 1 of 10 treatment sequences in a crossover design (5 x 1-week treatment periods separated by 7-10 day washout). Each sequence included twice daily RPL554 (0.15, 0.5, 1.5, or 3 mg) or matching placebo via DPI.
Participants by arm
| Arm | Count |
|---|---|
| 0.15 mg Single dose of RPL554 via DPI (double-blind) | 6 |
| 0.50 mg Single dose of RPL554 via DPI (double blind) | 6 |
| 1.5 mg Single dose of RPL554 via DPI (double blind) | 7 |
| 3 mg Single dose of RPL554 via DPI (double blind) | 6 |
| 6 mg Single dose of RPL554 via DPI (single blind) | 6 |
| Placebo Single dose via DPI (double blind) | 6 |
| Total | 37 |
Baseline characteristics
| Characteristic | 0.15 mg | Total | Placebo | 6 mg | 3 mg | 1.5 mg | 0.50 mg |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 61.7 years STANDARD_DEVIATION 10.15 | 59.5 years STANDARD_DEVIATION 7.57 | 60.8 years STANDARD_DEVIATION 8.8 | 59.3 years STANDARD_DEVIATION 7.81 | 52.7 years STANDARD_DEVIATION 3.88 | 63.7 years STANDARD_DEVIATION 6.68 | 58.3 years STANDARD_DEVIATION 3.56 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 35 Participants | 6 Participants | 6 Participants | 6 Participants | 5 Participants | 6 Participants |
| Region of Enrollment United States | 6 participants | 37 participants | 6 participants | 6 participants | 6 participants | 7 participants | 6 participants |
| Sex: Female, Male Female | 4 Participants | 23 Participants | 4 Participants | 2 Participants | 5 Participants | 3 Participants | 5 Participants |
| Sex: Female, Male Male | 2 Participants | 14 Participants | 2 Participants | 4 Participants | 1 Participants | 4 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 7 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 35 | 0 / 33 | 0 / 32 | 0 / 33 | 0 / 32 |
| other Total, other adverse events | 0 / 6 | 0 / 6 | 1 / 7 | 0 / 6 | 0 / 6 | 0 / 6 | 3 / 35 | 9 / 33 | 4 / 32 | 4 / 33 | 5 / 32 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 7 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 35 | 0 / 33 | 0 / 32 | 0 / 33 | 0 / 32 |
Outcome results
Primary
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)
RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose
Time frame: Day 1
Population: Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 260 h*pg/mL | Geometric Coefficient of Variation 53.5 |
| 0.50 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 472 h*pg/mL | Geometric Coefficient of Variation 106.7 |
| 1.5 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 2210 h*pg/mL | Geometric Coefficient of Variation 62.3 |
| 3 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 4160 h*pg/mL | Geometric Coefficient of Variation 47.2 |
| 6 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 9730 h*pg/mL | Geometric Coefficient of Variation 62.3 |
Primary
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)
RPL554 Area under the curve at maximum concentration after a single dose
Time frame: Day 1
Population: Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 222 h*pg/mL | Geometric Coefficient of Variation 55.5 |
| 0.50 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 495 h*pg/mL | Geometric Coefficient of Variation 128.2 |
| 1.5 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 2680 h*pg/mL | Geometric Coefficient of Variation 56.5 |
| 3 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 4920 h*pg/mL | Geometric Coefficient of Variation 44.5 |
| 6 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 11600 h*pg/mL | Geometric Coefficient of Variation 68.3 |
Primary
Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)
RPL554 Plasma pharmacokinetics Half-life concentration after a single dose
Time frame: Day 1
Population: Pharmacokinetic (PK) Analysis Set in Part A: all randomized patients who had blood sampling performed after the single dose of RPL554 and had evaluable PK parameter data. The PK Analysis Set included the 31 patients who received RPL554 in Part A but not the 6 patients in the placebo group.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 3.59 h | — |
| 0.50 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 5.39 h | Geometric Coefficient of Variation 28.7 |
| 1.5 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 7.48 h | Geometric Coefficient of Variation 43.3 |
| 3 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 6.65 h | Geometric Coefficient of Variation 33.6 |
| 6 mg | Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 6.66 h | Geometric Coefficient of Variation 25.4 |
Primary
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7
Time frame: Day 7
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.220 L | Standard Deviation 0.1593 |
| 0.50 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.293 L | Standard Deviation 0.2411 |
| 1.5 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.298 L | Standard Deviation 0.2355 |
| 3 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.378 L | Standard Deviation 0.2182 |
| 6 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.118 L | Standard Deviation 0.1437 |
p-value: <0.000195% CI: [1.138, 1.235]ANCOVA
p-value: <0.000195% CI: [1.088, 1.181]ANCOVA
p-value: <0.000195% CI: [1.089, 1.181]ANCOVA
p-value: 0.000195% CI: [1.041, 1.128]ANCOVA
Secondary
Part A: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose
Time frame: Day 1
Population: Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.045 L | Standard Deviation 0.0384 |
| 0.50 mg | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.113 L | Standard Deviation 0.1703 |
| 1.5 mg | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.214 L | Standard Deviation 0.2172 |
| 3 mg | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.243 L | Standard Deviation 0.2715 |
| 6 mg | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.176 L | Standard Deviation 0.0481 |
| Placebo | Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | -0.011 L | Standard Deviation 0.0749 |
p-value: 0.020895% CI: [1.024, 1.301]ANCOVA
p-value: 0.004195% CI: [1.064, 1.353]ANCOVA
p-value: 0.010895% CI: [1.039, 1.311]ANCOVA
p-value: 0.164195% CI: [0.965, 1.225]ANCOVA
Secondary
Part A: Change From Baseline in Average FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Population: Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.109 L | Standard Deviation 0.038 |
| 0.50 mg | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.213 L | Standard Deviation 0.1226 |
| 1.5 mg | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.326 L | Standard Deviation 0.249 |
| 3 mg | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.337 L | Standard Deviation 0.1831 |
| 6 mg | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.334 L | Standard Deviation 0.117 |
| Placebo | Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.040 L | Standard Deviation 0.0517 |
p-value: 0.000495% CI: [1.105, 1.365]ANCOVA
p-value: 0.000495% CI: [1.104, 1.365]ANCOVA
p-value: 0.001295% CI: [1.08, 1.326]ANCOVA
p-value: 0.034895% CI: [1.009, 1.246]ANCOVA
p-value: 0.310695% CI: [0.949, 1.172]ANCOVA
Secondary
Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Population: Full Analysis Set (FAS) in Part A: all randomized patients with sufficient data collected after intake of study medication to compute the PD parameters (FEV1 measurements pre dose and at least 1 post-baseline). All 37 patients randomized into Part A were included in the FAS.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.203 L | Standard Deviation 0.0646 |
| 0.50 mg | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.298 L | Standard Deviation 0.128 |
| 1.5 mg | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.429 L | Standard Deviation 0.2504 |
| 3 mg | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.468 L | Standard Deviation 0.2135 |
| 6 mg | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.452 L | Standard Deviation 0.1382 |
| Placebo | Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.135 L | Standard Deviation 0.0922 |
p-value: 0.000595% CI: [1.102, 1.369]ANCOVA
p-value: 0.000595% CI: [1.104, 1.372]ANCOVA
p-value: 0.002295% CI: [1.07, 1.32]ANCOVA
p-value: 0.065895% CI: [0.993, 1.233]ANCOVA
Secondary
Part A: Safety and Tolerability / Blood Chemistry Safety Assessments
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / ECG - Heart Rate
number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / ECG - QTcF
number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / Hematology Safety Assessments
number of patients with treatment-emergent hematology abnormal laboratory assessments
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure
number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp)
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate
Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose
Time frame: Day 1
Secondary
Part A: Safety and Tolerability / Urinalysis Safety Assessments
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: Day 1
Secondary
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1
Time frame: Day 1
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.101 L | Standard Deviation 0.1314 |
| 0.50 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.139 L | Standard Deviation 0.1921 |
| 1.5 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.135 L | Standard Deviation 0.1655 |
| 3 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.182 L | Standard Deviation 0.1536 |
| 6 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.044 L | Standard Deviation 0.1073 |
p-value: <0.000195% CI: [1.066, 1.141]ANCOVA
p-value: <0.000195% CI: [1.042, 1.116]ANCOVA
p-value: 0.000295% CI: [1.032, 1.104]ANCOVA
p-value: 0.006695% CI: [1.013, 1.084]ANCOVA
Secondary
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7
Time frame: Day 7
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.052 L | Standard Deviation 0.1759 |
| 0.50 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.106 L | Standard Deviation 0.2125 |
| 1.5 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.096 L | Standard Deviation 0.1796 |
| 3 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.163 L | Standard Deviation 0.1679 |
| 6 mg | Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.016 L | Standard Deviation 0.1455 |
p-value: <0.000195% CI: [1.078, 1.169]ANCOVA
p-value: 0.000495% CI: [1.035, 1.122]ANCOVA
p-value: 0.000295% CI: [1.039, 1.125]ANCOVA
p-value: 0.043795% CI: [1.001, 1.083]ANCOVA
Secondary
Part B: Change From Baseline in Average FEV1 (Over 4 Hours)
Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1
Time frame: Day 1
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.201 L | Standard Deviation 0.118 |
| 0.50 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.227 L | Standard Deviation 0.2026 |
| 1.5 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.268 L | Standard Deviation 0.1518 |
| 3 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.285 L | Standard Deviation 0.1597 |
| 6 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.079 L | Standard Deviation 0.1081 |
p-value: <0.000195% CI: [1.113, 1.189]ANCOVA
p-value: <0.000195% CI: [1.109, 1.185]ANCOVA
p-value: <0.000195% CI: [1.071, 1.144]ANCOVA
p-value: <0.000195% CI: [1.059, 1.13]ANCOVA
Secondary
Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)
Change from baseline in average FEV1 (over 4 hours) on Day 7
Time frame: Day 7
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.100 L | Standard Deviation 0.143 |
| 0.50 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.176 L | Standard Deviation 0.2253 |
| 1.5 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.184 L | Standard Deviation 0.2176 |
| 3 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.244 L | Standard Deviation 0.1953 |
| 6 mg | Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.017 L | Standard Deviation 0.1526 |
p-value: <0.000195% CI: [1.134, 1.234]ANCOVA
p-value: <0.000195% CI: [1.092, 1.19]ANCOVA
p-value: <0.000195% CI: [1.084, 1.18]ANCOVA
p-value: 0.000495% CI: [1.036, 1.126]ANCOVA
Secondary
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose
Time frame: Day 1
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.310 L | Standard Deviation 0.1382 |
| 0.50 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.332 L | Standard Deviation 0.2181 |
| 1.5 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.401 L | Standard Deviation 0.1705 |
| 3 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.404 L | Standard Deviation 0.1867 |
| 6 mg | Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.188 L | Standard Deviation 0.1267 |
p-value: <0.000195% CI: [1.106, 1.185]ANCOVA
p-value: <0.000195% CI: [1.109, 1.189]ANCOVA
p-value: <0.000195% CI: [1.062, 1.137]ANCOVA
p-value: <0.000195% CI: [1.052, 1.126]ANCOVA
Secondary
Part B: Change From Baseline in Peak Pulse Rate (Day 1)
Change from baseline in peak pulse after first dose on Day 1
Time frame: Day 1
Secondary
Part B: Change From Baseline in Peak Pulse Rate (Day 7)
Change from baseline in peak pulse after morning dosing on Day 7
Time frame: Day 7
Secondary
Part B: Change From Baseline in Trough FEV1
Change from Baseline FEV1 to Morning Trough FEV1 on Day 7
Time frame: Day 7
Population: All efficacy analyses were carried out using the Full Analysis Set (FAS) in Part B: all randomized patients with sufficient data (pre-dose and at least 1 post-dose assessment of spirometry) collected after intake of study medication to compute the PD parameters (FEV1, FRC measurements) on at least 2 treatment periods in Part B. The FAS comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: Change From Baseline in Trough FEV1 | -0.036 L | Standard Deviation 0.1332 |
| 0.50 mg | Part B: Change From Baseline in Trough FEV1 | 0.031 L | Standard Deviation 0.1821 |
| 1.5 mg | Part B: Change From Baseline in Trough FEV1 | 0.020 L | Standard Deviation 0.1838 |
| 3 mg | Part B: Change From Baseline in Trough FEV1 | 0.030 L | Standard Deviation 0.1539 |
| 6 mg | Part B: Change From Baseline in Trough FEV1 | -0.067 L | Standard Deviation 0.1577 |
p-value: 0.000695% CI: [1.038, 1.139]ANCOVA
p-value: 0.00195% CI: [1.034, 1.135]ANCOVA
p-value: 0.000295% CI: [1.047, 1.149]ANCOVA
p-value: 0.097195% CI: [0.993, 1.088]ANCOVA
Secondary
Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)
RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7
Time frame: Day 7
Population: Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | 263 h*pg/mL | Geometric Coefficient of Variation 56.2 |
| 0.50 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | 1240 h*pg/mL | Geometric Coefficient of Variation 52.3 |
| 1.5 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | 3070 h*pg/mL | Geometric Coefficient of Variation 73.6 |
| 3 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | 6460 h*pg/mL | Geometric Coefficient of Variation 49.9 |
Secondary
Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)
RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7
Time frame: Day 7
Population: Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 0.15 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | 68.7 pg/mL | Geometric Coefficient of Variation 41.6 |
| 0.50 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | 237 pg/mL | Geometric Coefficient of Variation 47.4 |
| 1.5 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | 591 pg/mL | Geometric Coefficient of Variation 71.1 |
| 3 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | 1240 pg/mL | Geometric Coefficient of Variation 41.4 |
Secondary
Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)
Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1
Time frame: Day 1
Population: Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 0.15 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 13.0 mins |
| 0.50 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 15 mins |
| 1.5 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 15 mins |
| 3 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 13 mins |
Secondary
Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)
RPL554 steady-state PK (tmax) after morning dose on Day 7
Time frame: Day 7
Population: Pharmacokinetic (PK) Analysis Set in Part B: all randomized patients who had blood sampling performed after at least 1 dose of RPL554 in Part B and with data sufficient to calculate PK parameters. The PK analysis set comprised: RPL554 0.15 mg (N=34); RPL554 0.5 mg (N=33); RPL554 1.5 mg (N=32); RPL554 3 mg (N=33); Placebo (N=32).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 0.15 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | 1.000 h |
| 0.50 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | 1.000 h |
| 1.5 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | 1.000 h |
| 3 mg | Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | 1.000 h |
Secondary
Part B: Safety and Tolerability / Blood Chemistry Safety Assessments
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / ECG - Heart Rate
number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / ECG - QTcF
number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / Hematology Safety Assessments
number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group).
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure
number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20)
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate
number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20
Time frame: Day 7
Secondary
Part B: Safety and Tolerability / Urinalysis Safety Assessments
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: Day 7